NCT03592875 is a clinical trial of Professional nurses in Nursing Personnel, sponsored by Luiz Carlos de Abreu.

Who is sponsoring NCT03592875?

NCT03592875 is sponsored by Luiz Carlos de Abreu.

What drugs are being tested in NCT03592875?

Interventions in NCT03592875: Professional nurses.

What condition does NCT03592875 study?

NCT03592875 studies Nursing Personnel.

Is NCT03592875 still recruiting?

NCT03592875 is currently status unknown. Last updated 30 July 2018.

Last reviewed 2018-07-30 · How we verify

NCT03592875

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of Knowledge and Practices in the Systematization of Nursing Care

Status unknown Last updated 30 July 2018

What this trial tests

trial testing Professional nurses in Nursing Personnel in 30 participants. Status unknown.

Timeline

15 August 2018

Primary endpoint
31 October 2018

30 December 2018

Quick facts

Lead sponsor	Luiz Carlos de Abreu
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	30
Start date	15 August 2018
Primary completion	31 October 2018
Estimated completion	30 December 2018

Drugs / interventions tested

Professional nurses

Conditions studied

Nursing Personnel — all drugs for Nursing Personnel →

Sponsor

Luiz Carlos de Abreu

Who can join

Adults 23 to 45, any sex, with Nursing Personnel. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective to analyse the performance of nurses in the implementation of Nursing Care Systematization - (NCS). This Study is a descriptive research developed from a qualitative approach. The content analysis must be developed through three chronological poles allowing the researcher to construct an analysis structure that corresponds to the needs of the research and the objectives of the proposed research; The chronological poles of content analysis are described as: Phase 1 - Pre-analysis, Phase 2 - Exploration of the material: Phase 3 - Treatment of the results obtained and interpretation. Only a semi-structured interview will be conducted with the research subjects who meet the inclusion criteria of the study, preserving the identity of the individuals and guaranteeing the right to quit the research at any time during the interview.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03592875 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Luiz Carlos de Abreu
Last refreshed: 30 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03592875.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing